Compare Marvell Technology Inc (MRVL) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marvell Technology Inc vs Novo Nordisk A/S — how do they compare? Marvell Technology Inc trades at $211.86 (market cap $171.11B), while Novo Nordisk A/S trades at $49.35 (market cap $220.53B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MRVL | NVO | |
|---|---|---|
Market Cap | $171.11B | $220.53B |
Sector | Technology | Health |
52-Week High | $316.43 | $71.70 |
52-Week Low | $62.31 | $35.29 |
Enterprise Value | $172.55B | $239.49B |
Dividend Yield | 0.12% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marvell Technology (MRVL) trades at $207.96, up 10.22% on the day, reflecting strong momentum amid AI-driven chip stock enthusiasm. The stock shows bearish technical signals but benefits from consistent earnings beats and robust analyst support with an 82% buy rating. Recent news highlights its 251% surge in H1 2026 and strategic positioning in AI infrastructure, though volatility persists due to sector-wide capex concerns. Fundamentals reveal high valuation multiples (P/E 66.99) against negative net income, offset by solid gross margins (51.5%) and projected revenue growth to $8.7B in 2026.
Outlook: MRVL offers growth exposure to AI networking and custom silicon, with a consensus price target of $275.68 implying 32% upside. Risks include execution challenges in scaling profitability, debt levels ($3.93B long-term), and sensitivity to AI spending cycles. The stock's premium valuation demands flawless execution to justify current levels amid competitive pressures.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marvell Technology Inc
Marvell Technology is a leading fabless chipmaker focused on networking and storage applications. Marvell serves the data center, carrier, enterprise, automotive, and consumer end markets with processors, optical interconnections, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications. The firm is an active acquirer, with five large acquisitions since 2017 helping it pivot out of legacy consumer applications to focus on the cloud and 5G markets.
Read more on MRVL →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
